世界の幹細胞市場2022-2030

【英語タイトル】GLOBAL STEM CELL MARKET FORECAST 2022-2030

Inkwood Researchが出版した調査資料(INK22NV012)・商品コード:INK22NV012
・発行会社(調査会社):Inkwood Research
・発行日:2022年9月
・ページ数:220
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・調査対象地域:グローバル
・産業分野:バイオ
◆販売価格オプション(消費税別)
Single UserUSD2,500 ⇒換算¥370,000見積依頼/購入/質問フォーム
Multi LicenseUSD3,000 ⇒換算¥444,000見積依頼/購入/質問フォーム
Enterprisewide PriceUSD4,500 ⇒換算¥666,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・送付(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
❖ レポートの概要 ❖

Inkwood Research社は、世界の幹細胞市場規模が、2022年から2030年の間に年平均8.88%成長すると予測しています。当書は、幹細胞の世界市場について調査・分析した内容をまとめており、調査範囲・手法、エグゼクティブサマリー、市場動向、主要分析、疾患別(整形外科治療、腫瘍性疾患、心血管疾患、神経疾患、その他)分析、製品別(成体幹細胞、ヒト胚性幹細胞、多能性幹細胞、マウス/ラット神経幹細胞)分析、技術別(細胞取得、細胞生産、凍結保存、拡大・継代培養)分析、用途別(再生医療、創薬・開発)分析、地域別(北米、ヨーロッパ、アジア太平洋、その他地域)分析、競争状況などの項目を掲載しております。なお、当書には、Corning Inc, GE Healthcare, Merck KGaA (Sigma Aldrich)などの企業情報が含まれています。
・調査範囲・手法
・エグゼクティブサマリー
・市場動向
・主要分析
・世界の幹細胞市場規模:治療目的別
- 整形外科治療における市場規模
- 腫瘍性疾患における市場規模
- 心血管疾患における市場規模
- 神経疾患における市場規模
- その他治療目的における市場規模
・世界の幹細胞市場規模:製品別
- 成体幹細胞の市場規模
- ヒト胚性幹細胞の市場規模
- 多能性幹細胞の市場規模
- マウス/ラット神経幹細胞の市場規模
・世界の幹細胞市場規模:技術別
- 細胞取得技術の市場規模
- 細胞生産技術の市場規模
- 凍結保存技術の市場規模
- 拡大・継代培養技術の市場規模
・世界の幹細胞市場規模:用途別
- 再生医療における市場規模
- 創薬・開発における市場規模
・世界の幹細胞市場規模:地域別
- 北米の幹細胞市場規模
- ヨーロッパの幹細胞市場規模
- アジア太平洋の幹細胞市場規模
- その他地域の幹細胞市場規模
・競争状況

KEY FINDINGS
The global stem cell market is predicted to grow with a CAGR of 8.88% during the forecasted years of 2022 to 2030. The growth of the market is determined by key drivers such as the increasing demand for stem cells in regenerative medicine, the rising &D investments in stem cell therapies and research, the growing awareness about umbilical cord stem cells, and the reduced risk of tissue rejection in transplants.

MARKET INSIGHTS
Stem cells are characterized as special human cells with the ability to develop into several different cell types, ranging from brain cells to muscle cells. In-depth research is now being done on various cell types, including mesenchymal stem cells, epithelial stem cells, resident tissue stem cells, embryonic stem cells, hematopoietic stem cells, as well as adipose-derived stem cells.
Regenerative medicine helps produce functional, living tissues to repair aged or diseased tissue; and is therefore utilized in the treatment of cardiovascular, orthopedic, neural, and autoimmune conditions. Regenerative medicine formerly included bioabsorbable scaffolds as well as other biochemical materials. Stem cell technology is also venturing into the avenue of regenerative medicine, as embryonic stem cells possess the potential to differentiate into and subsequently regenerate all kinds of tissues. As a result, the increasing demand for stem cells in regenerative medicine is anticipated to propel the global stem cell market growth.

REGIONAL INSIGHTS
The global stem cell market growth assessment comprises the evaluation of North America, the Asia-Pacific, Europe, and Rest of World. North America is projected to dominate the global market during the forecasted years on account of factors such as technological advancements in stem cell preservation and manufacturing, industry players’ substantial investments in R&D activities, and the surging public awareness of stem cell products’ therapeutic potential.

COMPETITIVE INSIGHTS
Over the forecast period, the intensity of industrial rivalry within the global stem cell market is expected to increase and remain high. Some of the top players operating in the global market are Corning Inc, GE Healthcare, Merck KGaA (Sigma Aldrich), etc.

Our report offerings include:
• Explore key findings of the overall market
• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
• Market Segmentation cater to a thorough assessment of key segments with their market estimations
• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
• Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
• Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

❖ レポートの目次 ❖

TABLE OF CONTENTS
1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. SCOPE OF STUDY
1.3. METHODOLOGY
1.4. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
3. MARKET DYNAMICS
3.1. KEY DRIVERS
3.1.1. SURGING DEMAND FOR STEM CELLS IN REGENERATIVE MEDICINE
3.1.2. GROWING R&D INVESTMENTS IN STEM CELL THERAPIES & RESEARCH
3.1.3. RISING AWARENESS ABOUT UMBILICAL CORD STEM CELLS
3.1.4. REDUCED RISK OF TISSUE REJECTION IN TRANSPLANTS
3.2. KEY RESTRAINTS
3.2.1. ABSENCE OF A WELL-DEFINED REGULATORY FRAMEWORK FOR STEM CELL THERAPY
3.2.2. HIGH COSTS ASSOCIATED WITH STEM CELL PROCEDURES
3.2.3. ETHICAL ISSUES AND SOCIAL COMPLEXITIES
3.2.4. LESS RESPONSIVENESS IN DEVELOPED ECONOMIES
4. KEY ANALYTICS
4.1. IMPACT OF COVID-19 ON STEM CELL MARKET
4.2. KEY MARKET TRENDS
4.3. PORTER’S FIVE FORCES ANALYSIS
4.3.1. BUYERS POWER
4.3.2. SUPPLIERS POWER
4.3.3. SUBSTITUTION
4.3.4. NEW ENTRANTS
4.3.5. INDUSTRY RIVALRY
4.4. OPPORTUNITY MATRIX
4.5. VENDOR LANDSCAPE
4.6. VALUE CHAIN ANALYSIS
4.7. KEY BUYING CRITERIA
4.7.1. PRICE
4.7.2. EFFICACY
4.7.3. APPLICATION AND EFFECTIVENESS
4.7.4. ACCURACY
4.8. REGULATORY FRAMEWORK
5. MARKET BY THERAPEUTIC APPLICATION
5.1. ORTHOPEDIC TREATMENTS
5.2. INJURIES & WOUNDS
5.3. ONCOLOGY DISORDERS
5.4. CARDIOVASCULAR DISORDERS
5.5. NEUROLOGICAL DISORDERS
5.6. DIABETES
5.7. OTHER THERAPEUTIC APPLICATIONS
6. MARKET BY PRODUCT
6.1. ADULT STEM CELL
6.1.1. HEMATOPOIETIC STEM CELL
6.1.2. NEURAL STEM CELL
6.1.3. UMBILICAL CORD STEM CELL
6.1.4. MESENCHYMAL STEM CELL
6.1.5. DENTAL STEM CELL
6.2. HUMAN EMBRYONIC STEM CELL
6.3. PLURIPOTENT
6.4. MOUSE/RAT NEURAL
7. MARKET BY TECHNOLOGY
7.1. CELL ACQUISITION
7.1.1. BONE MARROW HARVEST
7.1.2. UMBILICAL CORD
7.1.3. APHERESIS
7.2. CELL PRODUCTION
7.2.1. THERAPEUTIC CLONING
7.2.2. IN VITRO FERTILIZATION (IVF)
7.2.3. CELL CULTURE
7.2.4. ISOLATION
7.3. CRYOPRESERVATION
7.4. EXPANSION & SUB-CULTURE
8. MARKET BY APPLICATION
8.1. REGENERATIVE MEDICINE
8.2. DRUG DISCOVERY AND DEVELOPMENT
9. MARKET BY TREATMENT TYPE
9.1. ALLOGENEIC STEM CELL THERAPY
9.2. AUTOLOGIC STEM CELL THERAPY
9.3. SYNGENEIC STEM CELL THERAPY
10. GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1. MARKET SIZE & ESTIMATES
10.1.2. KEY GROWTH ENABLERS
10.1.3. KEY CHALLENGES
10.1.4. KEY PLAYERS
10.1.5. COUNTRY ANALYSIS
10.1.5.1. UNITED STATES
10.1.5.2. CANADA
10.2. EUROPE
10.2.1. MARKET SIZE & ESTIMATES
10.2.2. KEY GROWTH ENABLERS
10.2.3. KEY CHALLENGES
10.2.4. KEY PLAYERS
10.2.5. COUNTRY ANALYSIS
10.2.5.1. UNITED KINGDOM
10.2.5.2. GERMANY
10.2.5.3. FRANCE
10.2.5.4. ITALY
10.2.5.5. BELGIUM
10.2.5.6. POLAND
10.2.5.7. REST OF EUROPE
10.3. ASIA-PACIFIC
10.3.1. MARKET ESTIMATES & SIZES
10.3.2. KEY GROWTH ENABLERS
10.3.3. KEY CHALLENGES
10.3.4. KEY PLAYERS
10.3.5. COUNTRY ANALYSIS
10.3.5.1. CHINA
10.3.5.2. JAPAN
10.3.5.3. INDIA
10.3.5.4. AUSTRALIA & NEW ZEALAND
10.3.5.5. SOUTH KOREA
10.3.5.6. THAILAND
10.3.5.7. INDONESIA
10.3.5.8. VIETNAM
10.3.5.9. REST OF ASIA-PACIFIC
10.4. REST OF WORLD
10.4.1. MARKET ESTIMATES & SIZES
10.4.2. KEY GROWTH ENABLERS
10.4.3. KEY CHALLENGES
10.4.4. KEY PLAYERS
10.4.5. REGIONAL ANALYSIS
10.4.5.1. LATIN AMERICA
10.4.5.2. MIDDLE EAST & AFRICA
11. COMPETITIVE LANDSCAPE
11.1. KEY STRATEGIC DEVELOPMENTS
11.1.1. ACQUISITIONS
11.1.2. PARTNERSHIPS
11.2. COMPANY PROFILES
11.2.1. ALLCELLS LLC
11.2.2. BECTON, DICKINSON AND COMPANY (BD)
11.2.3. CORNING INC
11.2.4. GE HEALTHCARE
11.2.5. INTERNATIONAL STEM CELL CORPORATION
11.2.6. LOREM CYTORI INC
11.2.7. MERCK KGAA (SIGMA ALDRICH)
11.2.8. MILTENYI BIOTEC
11.2.9. PLURI INC
11.2.10. QIAGEN
11.2.11. SMITH+NEPHEW PLC
11.2.12. STEMCELL TECHNOLOGIES INC
11.2.13. STRYKER CORPORATION
11.2.14. TAKARA HOLDINGS INC
11.2.15. THERMO FISHER SCIENTIFIC INC



★調査レポート[世界の幹細胞市場2022-2030] (コード:INK22NV012)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の幹細胞市場2022-2030]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆